1887

Abstract

Colorectal cancer (CRC) is the third most common form of cancer. Diverse therapies such as chemotherapy, immunotherapy and radiation have shown beneficial effects, but are limited because of their safety and toxicity. Probiotic formulations have shown great promise in CRC as preventive and early stage therapeutics. This review highlights the importance of a balanced intestinal microbiota and summarizes the recent developments in probiotics for treating CRC. Specifically, this report describes evidence of the role of probiotics in modulating the microbiota, in improving the physico-chemical conditions of the gut and in reducing oxidative stress. It also discusses the mechanisms of probiotics in inhibiting tumour progression, in producing anticancer compounds and in modulating the host immune response. Even though some of these effects were observed in several clinical trials, when probiotic formulations were used as a supplement to CRC therapies, the application of probiotics as biotherapeutics against CRC still needs further investigation.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.048975-0
2013-08-01
2024-11-07
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/8/1107.html?itemId=/content/journal/jmm/10.1099/jmm.0.048975-0&mimeType=html&fmt=ahah

References

  1. Abdelali H., Cassand P., Soussotte V., Daubeze M., Bouley C., Narbonne J. F. 1995; Effect of dairy products on initiation of precursor lesions of colon cancer in rats. Nutr Cancer 24:121–132 [View Article][PubMed]
    [Google Scholar]
  2. Ahmed F. E. 2007; Colorectal cancer epigenetics: the role of environmental factors and the search for molecular biomarkers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25:101–154 [View Article][PubMed]
    [Google Scholar]
  3. Altonsy M. O., Andrews S. C., Tuohy K. M. 2010; Differential induction of apoptosis in human colonic carcinoma cells (Caco-2) by Atopobium, and commensal, probiotic and enteropathogenic bacteria: mediation by the mitochondrial pathway. Int J Food Microbiol 137:190–203 [View Article][PubMed]
    [Google Scholar]
  4. Amasheh S., Milatz S., Krug S. M., Markov A. G., Günzel D., Amasheh M., Fromm M. 2009; Tight junction proteins as channel formers and barrier builders. Ann N Y Acad Sci 1165:211–219 [View Article][PubMed]
    [Google Scholar]
  5. An H. M., Baek E. H., Jang S., Lee K., Kim M. J., Kim J. R., Lee K. O., Park J. G., Ha N. J. 2010; Efficacy of lactic acid bacteria (LAB) supplement in management of constipation among nursing home residents. Nutr J 9:5 [View Article][PubMed]
    [Google Scholar]
  6. An H. M., Park S. Y., Lee K., Kim J. R., Cha M. K., Lee S. W., Lim H. T., Kim K. J., Ha N. J. 2011; Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis 10:116 [View Article][PubMed]
    [Google Scholar]
  7. Apás A. L., Dupraz J., Ross R., González S. N., Arena M. E. 2010; Probiotic administration effect on fecal mutagenicity and microflora in the goat’s gut. J Biosci Bioeng 110:537–540 [View Article][PubMed]
    [Google Scholar]
  8. Arthur J. C., Jobin C. 2011; The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis 17:396–409 [View Article][PubMed]
    [Google Scholar]
  9. Azcárate-Peril M. A., Sikes M., Bruno-Bárcena J. M. 2011; The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer?. Am J Physiol Gastrointest Liver Physiol 301:G401–G424 [View Article][PubMed]
    [Google Scholar]
  10. Baldwin C., Millette M., Oth D., Ruiz M. T., Luquet F. M., Lacroix M. 2010; Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr Cancer 62:371–378 [View Article][PubMed]
    [Google Scholar]
  11. Barker N., Ridgway R. A., van Es J. H., van de Wetering M., Begthel H., van den Born M., Danenberg E., Clarke A. R., Sansom O. J., Clevers H. 2009; Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457:608–611 [View Article][PubMed]
    [Google Scholar]
  12. Bassaganya-Riera J., Hontecillas R. 2010; Dietary CLA and n-3 PUFA in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 13:569 [View Article][PubMed]
    [Google Scholar]
  13. Bassaganya-Riera J., Hontecillas R., Beitz D. C. 2002; Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 21:451–459 [View Article][PubMed]
    [Google Scholar]
  14. Bertkova I., Hijova E., Chmelarova A., Mojzisova G., Petrasova D., Strojny L., Bomba A., Zitnan R. 2010; The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats. Neoplasma 57:422–428 [View Article][PubMed]
    [Google Scholar]
  15. Boleij A., Tjalsma H. 2012; Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. Biol Rev Camb Philos Soc 87:701–730 [View Article][PubMed]
    [Google Scholar]
  16. Bolognani F., Rumney C. J., Rowland I. R. 1997; Influence of carcinogen binding by lactic acid-producing bacteria on tissue distribution and in vivo mutagenicity of dietary carcinogens. Food Chem Toxicol 35:535–545 [View Article][PubMed]
    [Google Scholar]
  17. Bomba A., Brandeburová A., Ričanyová J., Strojný L., Chmelárová A., Szabadosová V., Pramuková B., Žofčáková J., Salaj R. other authors 2012; The role of probiotics and natural bioactive compounds in modulation of the common molecular pathways in pathogenesis of atherosclerosis and cancer. Biologia 67:1–13 [View Article]
    [Google Scholar]
  18. Borowicki A., Michelmann A., Stein K., Scharlau D., Scheu K., Obst U., Glei M. 2011; Fermented wheat aleurone enriched with probiotic strains LGG and Bb12 modulates markers of tumor progression in human colon cells. Nutr Cancer 63:151–160[PubMed]
    [Google Scholar]
  19. Castellarin M., Warren R. L., Freeman J. D., Dreolini L., Krzywinski M., Strauss J., Barnes R., Watson P., Allen-Vercoe E. other authors 2012; Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22:299–306 [View Article][PubMed]
    [Google Scholar]
  20. Cheah P. Y. 1990; Hypotheses for the etiology of colorectal cancer–an overview. Nutr Cancer 14:5–13 [View Article][PubMed]
    [Google Scholar]
  21. Chen X., Fruehauf J., Goldsmith J. D., Xu H., Katchar K. K., Koon H. W., Zhao D., Kokkotou E. G., Pothoulakis C., Kelly C. P. 2009; Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology 137:914–923 [View Article][PubMed]
    [Google Scholar]
  22. Chung K. T., Stevens S. E. Jr, Cerniglia C. E. 1992; The reduction of azo dyes by the intestinal microflora. Crit Rev Microbiol 18:175–190 [View Article][PubMed]
    [Google Scholar]
  23. Circu M. L., Aw T. Y. 2012; Intestinal redox biology and oxidative et stress. Semin Cell Dev Biol 23729–737 [CrossRef]
    [Google Scholar]
  24. Clark M. J., Robien K., Slavin J. L. 2012; Effect of prebiotics on biomarkers of colorectal cancer in humans: a systematic review. Nutr Rev 70:436–443 [View Article][PubMed]
    [Google Scholar]
  25. Collado M. C., Isolauri E., Salminen S., Sanz Y. 2009; The impact of probiotic on gut health. Curr Drug Metab 10:68–78 [View Article][PubMed]
    [Google Scholar]
  26. Cross A. J., Sinha R. 2004; Meat-related mutagens/carcinogens in the etiology of colorectal cancer. Environ Mol Mutagen 44:44–55 [View Article][PubMed]
    [Google Scholar]
  27. Cummings J. G. 1975; The colon: Absorptive, seccretory and metabolic functions. Digestion 13:232–240 [View Article][PubMed]
    [Google Scholar]
  28. Davis C. D., Milner J. A. 2009; Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem 20:743–752 [View Article][PubMed]
    [Google Scholar]
  29. de Miranda N. F., Nielsen M., Pereira D., van Puijenbroek M., Vasen H. F., Hes F. J., van Wezel T., Morreau H. 2009; MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers. J Pathol 219:69–76 [View Article][PubMed]
    [Google Scholar]
  30. De Preter V., Hamer H. M., Windey K., Verbeke K. 2011; The impact of pre- and/or probiotics on human colonic metabolism: does it affect human health?. Mol Nutr Food Res 55:46–57 [View Article][PubMed]
    [Google Scholar]
  31. Del Piano M., Carmagnola S., Andorno S., Pagliarulo M., Tari R., Mogna L., Strozzi G. P., Sforza F., Capurso L. 2010; Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. J Clin Gastroenterol 44:Suppl 1S42–S46 [View Article][PubMed]
    [Google Scholar]
  32. Del Piano M., Carmagnola S., Ballarè M., Sartori M., Orsello M., Balzarini M., Pagliarulo M., Tari R., Anderloni A. other authors 2011; Is microencapsulation the future of probiotic preparations? The increased efficacy of gastro-protected probiotics. Gut Microbes 2:120–123 [View Article][PubMed]
    [Google Scholar]
  33. Eaton D. L., Gallagher E. P. 1994; Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 34:135–172 [View Article][PubMed]
    [Google Scholar]
  34. Ehlers S., Kaufmann S. H. E. Participants of the 99(th) Dahlem Conference 2010; Infection, inflammation, and chronic diseases: consequences of a modern lifestyle. Trends Immunol 31:184–190 [View Article][PubMed]
    [Google Scholar]
  35. El-Nezami H., Kankaanpaa P., Salminen S., Ahokas J. 1998; Ability of dairy strains of lactic acid bacteria to bind a common food carcinogen, aflatoxin B1. Food Chem Toxicol 36:321–326 [View Article][PubMed]
    [Google Scholar]
  36. Elmadfa I., Klein P., Meyer A. L. 2010; Immune-stimulating effects of lactic acid bacteria in vivo and in vitro. Proc Nutr Soc 69:416–420 [View Article][PubMed]
    [Google Scholar]
  37. Ewaschuk J. B., Walker J. W., Diaz H., Madsen K. L. 2006; Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr 136:1483–1487[PubMed]
    [Google Scholar]
  38. FAO/WHO 2006 Probiotics in Food. Health and Nutritional Properties and Guidelines for Evaluation Rome: FAO Food and Nutrition;
    [Google Scholar]
  39. Floch M. H. 2010; The effect of probiotics on host metabolism: the microbiota and fermentation. J Clin Gastroenterol 44:Suppl 1S19–S21 [View Article][PubMed]
    [Google Scholar]
  40. Fotiadis C. I., Stoidis C. N., Spyropoulos B. G., Zografos E. D. 2008; Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol 14:6453–6457 [View Article][PubMed]
    [Google Scholar]
  41. Frank D. N., St Amand A. L., Feldman R. A., Boedeker E. C., Harpaz N., Pace N. R. 2007; Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785 [View Article][PubMed]
    [Google Scholar]
  42. Fujisawa T., Mori M. 1996; Influence of bile salts on β-glucuronidase activity of intestinal bacteria. Lett Appl Microbiol 22:271–274 [View Article][PubMed]
    [Google Scholar]
  43. Gareau M. G., Sherman P. M., Walker W. A. 2010; Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7:503–514 [View Article][PubMed]
    [Google Scholar]
  44. Gianotti L., Morelli L., Galbiati F., Rocchetti S., Coppola S., Beneduce A., Gilardini C., Zonenschain D., Nespoli A., Braga M. 2010; A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol 16:167–175 [View Article][PubMed]
    [Google Scholar]
  45. Gorbach S. L., Goldin B. R. 1990; The intestinal microflora and the colon cancer connection. Rev Infect Dis 12:Suppl 2S252–S261 [View Article][PubMed]
    [Google Scholar]
  46. Gozuacik D., Kimchi A. 2004; Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891–2906 [View Article][PubMed]
    [Google Scholar]
  47. Grimoud J., Durand H., de Souza S., Monsan P., Ouarné F., Theodorou V., Roques C. 2010; In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. Int J Food Microbiol 144:42–50 [View Article][PubMed]
    [Google Scholar]
  48. Grishina A., Kulikova I., Alieva L., Dodson A., Rowland I., Jin J. 2011; Antigenotoxic effect of kefir and ayran supernatants on fecal water-induced DNA damage in human colon cells. Nutr Cancer 63:73–79[PubMed]
    [Google Scholar]
  49. Guarner F., Malagelada J. R. 2003; Gut flora in health and disease. Lancet 361:512–519 [View Article][PubMed]
    [Google Scholar]
  50. Hambly R. J., Rumney C. J., Fletcher J. M., Rijken P. J., Rowland I. R. 1997; Effects of high- and low-risk diets on gut microflora-associated biomarkers of colon cancer in human flora-associated rats. Nutr Cancer 27:250–255 [View Article][PubMed]
    [Google Scholar]
  51. Hancock V., Dahl M., Klemm P. 2010; Probiotic Escherichia coli strain Nissle 1917 outcompetes intestinal pathogens during biofilm formation. J Med Microbiol 59:392–399 [View Article][PubMed]
    [Google Scholar]
  52. Horvat M., Krebs B., Potrc S., Ivanecz A., Kompan L. 2010; Preoperative synbiotic bowel conditioning for elective colorectal surgery. Wien Klin Wochenschr 122:Suppl 226–30 [View Article][PubMed]
    [Google Scholar]
  53. Iacono A., Raso G. M., Canani R. B., Calignano A., Meli R. 2011; Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 22:699–711 [View Article][PubMed]
    [Google Scholar]
  54. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. 2011; Global cancer statistics. CA Cancer J Clin 61:69–90 [View Article][PubMed]
    [Google Scholar]
  55. Jensen R., Buffangeix D., Covi G. 1976; Measuring water content of feces by the Karl Fischer method. Clin Chem 22:1351–1354[PubMed]
    [Google Scholar]
  56. Jones M. L., Tomaro-Duchesneau C., Martoni C. J., Prakash S. 2013; Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opin Biol Ther 13:631–642 [View Article][PubMed]
    [Google Scholar]
  57. Kailasapathy K. 2002; Microencapsulation of probiotic bacteria: technology and potential applications. Curr Issues Intest Microbiol 3:39–48[PubMed]
    [Google Scholar]
  58. Karczewski J., Troost F. J., Konings I., Dekker J., Kleerebezem M., Brummer R. J., Wells J. M. 2010; Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 298:G851–G859 [View Article][PubMed]
    [Google Scholar]
  59. Karin M., Lawrence T., Nizet V. 2006; Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124:823–835 [View Article][PubMed]
    [Google Scholar]
  60. Kekkonen R. A., Holma R., Hatakka K., Suomalainen T., Poussa T., Adlercreutz H., Korpela R. 2011; A probiotic mixture including galactooligosaccharides decreases fecal β-glucosidase activity but does not affect serum enterolactone concentration in men during a two-week intervention. J Nutr 141:870–876 [View Article][PubMed]
    [Google Scholar]
  61. Kelloff G. J., Boone C. W., Crowell J. A., Nayfield S. G., Hawk E., Malone W. F., Steele V. E., Lubet R. A., Sigman C. C. 1996; Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 63:S251–14 [View Article][PubMed]
    [Google Scholar]
  62. Khailova L., Mount Patrick S. K., Arganbright K. M., Halpern M. D., Kinouchi T., Dvorak B. 2010; Bifidobacterium bifidum reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 299:G1118–G1127 [View Article][PubMed]
    [Google Scholar]
  63. Kim D. H., Kang H. J., Park S. H., Kobashi K. 1994; Characterization of beta-glucosidase and beta-glucuronidase of alkalotolerant intestinal bacteria. Biol Pharm Bull 17:423–426 [View Article][PubMed]
    [Google Scholar]
  64. Kim Y., Lee D., Kim D., Cho J., Yang J., Chung M., Kim K., Ha N. 2008; Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Arch Pharm Res 31:468–473 [View Article][PubMed]
    [Google Scholar]
  65. Kim Y., Oh S., Yun H. S., Oh S., Kim S. H. 2010; Cell-bound exopolysaccharide from probiotic bacteria induces autophagic cell death of tumour cells. Lett Appl Microbiol 51:123–130[PubMed]
    [Google Scholar]
  66. Kimura I., Inoue D., Maeda T., Hara T., Ichimura A., Miyauchi S., Kobayashi M., Hirasawa A., Tsujimoto G. 2011; Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 108:8030–8035 [View Article][PubMed]
    [Google Scholar]
  67. Klaenhammer T. R., Kleerebezem M., Kopp M. V., Rescigno M. 2012; The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol 12:728–734 [View Article][PubMed]
    [Google Scholar]
  68. Kleerebezem M., Vaughan E. E. 2009; Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. Annu Rev Microbiol 63:269–290 [View Article][PubMed]
    [Google Scholar]
  69. Kleessen B., Blaut M. 2005; Modulation of gut mucosal biofilms. Br J Nutr 93:Suppl 1S35–S40 [View Article][PubMed]
    [Google Scholar]
  70. Ko J. S., Yang H. R., Chang J. Y., Seo J. K. 2007; Lactobacillus plantarum inhibits epithelial barrier dysfunction and interleukin-8 secretion induced by tumor necrosis factor-alpha. World J Gastroenterol 13:1962–1965[PubMed] [CrossRef]
    [Google Scholar]
  71. Kono S. 2011; [Lifestyle and environmental factors for colorectal cancer]. Nihon Rinsho 69:Suppl 351–54 (in Japanese) [PubMed]
    [Google Scholar]
  72. Kostic A. D., Gevers D., Pedamallu C. S., Michaud M., Duke F., Earl A. M., Ojesina A. I., Jung J., Bass A. J. other authors 2012; Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22:292–298 [View Article][PubMed]
    [Google Scholar]
  73. Kruszewska D., Lan J., Lorca G., Yanagisawa N., Marklinder I., Ljungh Å. 2002; Selection of lactic acid bacteria as probiotic strains by in vitro tests. Microecol Therapy 29:37–49
    [Google Scholar]
  74. Kumar A., Wu H., Collier-Hyams L. S., Hansen J. M., Li T., Yamoah K., Pan Z. Q., Jones D. P., Neish A. S. 2007; Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J 26:4457–4466 [View Article][PubMed]
    [Google Scholar]
  75. Kumar A., Singh N. K., Sinha P. R. 2010; Inhibition of 1,2-dimethylhydrazine induced colon genotoxicity in rats by the administration of probiotic curd. Mol Biol Rep 37:1373–1376 [View Article][PubMed]
    [Google Scholar]
  76. Kumar R. S., Kanmani P., Yuvaraj N., Paari K. A., Pattukumar V., Thirunavukkarasu C., Arul V. 2012; Lactobacillus plantarum AS1 isolated from south Indian fermented food Kallappam suppress 1,2-dimethyl hydrazine (DMH)-induced colorectal cancer in male Wistar rats. Appl Biochem Biotechnol 166:620–631 [View Article][PubMed]
    [Google Scholar]
  77. Kumar M., Nagpal R., Verma V., Kumar A., Kaur N., Hemalatha R., Gautam S. K., Singh B. 2013; Probiotic metabolites as epigenetic targets in the prevention of colon cancer. Nutr Rev 71:23–34 [View Article][PubMed]
    [Google Scholar]
  78. Lai L. R., Hsieh S. C., Huang H. Y., Chou C. C. 2013; Effect of lactic fermentation on the total phenolic, saponin and phytic acid contents as well as anti-colon cancer cell proliferation activity of soymilk. J Biosci Bioeng 115:552–556 [View Article][PubMed]
    [Google Scholar]
  79. Lan A., Lagadic-Gossmann D., Lemaire C., Brenner C., Jan G. 2007; Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. Apoptosis 12:573–591 [View Article][PubMed]
    [Google Scholar]
  80. Le Leu R. K., Hu Y., Brown I. L., Woodman R. J., Young G. P. 2010; Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. Carcinogenesis 31:246–251 [View Article][PubMed]
    [Google Scholar]
  81. Lee D. K., Jang S., Kim M. J., Kim J. H., Chung M. J., Kim K. J., Ha N. J. 2008; Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines. BMC Cancer 8:310 [View Article][PubMed]
    [Google Scholar]
  82. Lee D. K., Jang S., Baek E. H., Kim M. J., Lee K. S., Shin H. S., Chung M. J., Kim J. E., Lee K. O., Ha N. J. 2009; Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content. Lipids Health Dis 8:21 [View Article][PubMed]
    [Google Scholar]
  83. Liboredo J. C., Anastácio L. R., Mattos L. V., Nicoli J. R., Correia M. I. T. D. 2010; Impact of probiotic supplementation on mortality of induced 1,2-dimethylhydrazine carcinogenesis in a mouse model. Nutrition 26:779–783 [View Article][PubMed]
    [Google Scholar]
  84. Linsalata M., Russo F. 2008; Nutritional factors and polyamine metabolism in colorectal cancer. Nutrition 24:382–389 [View Article][PubMed]
    [Google Scholar]
  85. Linsalata M., Cavallini A., Messa C., Orlando A., Refolo M. G., Russo F. 2010; Lactobacillus rhamnosus GG influences polyamine metabolism in HGC-27 gastric cancer cell line: a strategy toward nutritional approach to chemoprevention of gastric cance. Curr Pharm Des 16:847–853 [View Article][PubMed]
    [Google Scholar]
  86. Liong M. T. 2008; Roles of probiotics and prebiotics in colon cancer prevention: Postulated mechanisms and in-vivo evidence. Int J Mol Sci 9:854–863 [View Article][PubMed]
    [Google Scholar]
  87. Liu Z., Qin H., Yang Z., Xia Y., Liu W., Yang J., Jiang Y., Zhang H., Yang Z. other authors 2011; Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery - a double-blind study. Aliment Pharmacol Ther 33:50–63 [View Article][PubMed]
    [Google Scholar]
  88. Ma E. L., Choi Y. J., Choi J., Pothoulakis C., Rhee S. H., Im E. 2010; The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. Int J Cancer 127:780–790[PubMed]
    [Google Scholar]
  89. Madsen K. L. 2012; Enhancement of epithelial barrier function by probiotics. J Epithel Biol Pharmacol 5:55–59 [View Article]
    [Google Scholar]
  90. Mai V., McCrary Q. M., Sinha R., Glei M. 2009; Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and Caucasian American volunteers. Nutr J 8:49 [View Article][PubMed]
    [Google Scholar]
  91. Mal M., Koh P. K., Cheah P. Y., Chan E. C. Y. 2012; Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal Bioanal Chem 403:483–493 [View Article][PubMed]
    [Google Scholar]
  92. McBain A. J., Macfarlane G. T. 1998; Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites. J Med Microbiol 47:407–416 [View Article][PubMed]
    [Google Scholar]
  93. McConnell E. L., Short M. D., Basit A. W. 2008; An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J Control Release 130:154–160 [View Article][PubMed]
    [Google Scholar]
  94. McGarr S. E., Ridlon J. M., Hylemon P. B. 2005; Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol 39:98–109[PubMed]
    [Google Scholar]
  95. Mego M., Májek J., Konceková R., Ebringer L., Cierniková S., Rauko P., Kovác M., Trupl J., Slezák P., Zajac V. 2005; Intramucosal bacteria in colon cancer and their elimination by probiotic strain Enterococcus faecium M-74 with organic selenium. Folia Microbiol (Praha) 50:443–447 [View Article][PubMed]
    [Google Scholar]
  96. Mladenova D., Daniel J. J., Dahlstrom J. E., Bean E., Gupta R., Pickford R., Currey N., Musgrove E. A., Kohonen-Corish M. R. 2011; The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 60:350–360 [View Article][PubMed]
    [Google Scholar]
  97. Mennigen R., Nolte K., Rijcken E., Utech M., Loeffler B., Senninger N., Bruewer M. 2009; Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296:G1140–G1149 [View Article][PubMed]
    [Google Scholar]
  98. Nancey S., Coffin B., Descos L., Flourié B. 2001; Colonic microflora and cancer. Gastroenterol Clin Biol 25:C79–C84 (in French) [PubMed]
    [Google Scholar]
  99. Nanno M., Kato I., Kobayashi T., Shida K. 2011; Biological effects of probiotics: what impact does Lactobacillus casei shirota have on us?. Int J Immunopathol Pharmacol 24:Suppl45S–50S[PubMed]
    [Google Scholar]
  100. Nau J. Y. 2011; [What is done with a normal gut microbiota?]. Rev Med Suisse 7:1434–1435 (in French) [PubMed]
    [Google Scholar]
  101. Ochmański W., Barabasz W. 1999; [Probiotics and their therapeutic properties]. Przegl Lek 56:211–215 (in Polish) [PubMed]
    [Google Scholar]
  102. Ohara T., Yoshino K., Kitajima M. 2009; [Pre- and probiotics increase host-cell immunological competence, improve bowel movement, and prevent the onset of colon cancer–an analysis based on movements of intestinal microbiota]. Rinsho Byori 57:533–541 (in Japanese) [PubMed]
    [Google Scholar]
  103. Ohara T., Yoshino K., Kitajima M. 2010; Possibility of preventing colorectal carcinogenesis with probiotics. Hepatogastroenterology 57:1411–1415[PubMed]
    [Google Scholar]
  104. Ohkawara S., Furuya H., Nagashima K., Asanuma N., Hino T. 2005; Oral administration of Butyrivibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. J Nutr 135:2878–2883[PubMed]
    [Google Scholar]
  105. Ohno K., Narushima S., Takeuchi S., Itoh K., Itoh T., Hioki K., Nomura T. 2001; Effect of bacterial metabolism in the intestine on colorectal tumors induced by 1,2-dimethylhydrazine in transgenic mice harboring human prototype c-Ha-ras genes. J Exp Clin Cancer Res 20:51–56[PubMed]
    [Google Scholar]
  106. Olejnik A., Tomczyk J., Kowalska K., Grajek W. 2010; [The role of natural dietary compounds in colorectal cancer chemoprevention]. Postepy Hig Med Dosw (Online) 64:175–187 (in Polish) [PubMed]
    [Google Scholar]
  107. Österlund P., Ruotsalainen T., Korpela R., Saxelin M., Ollus A., Valta P., Kouri M., Elomaa I., Joensuu H. 2007; Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97:1028–1034 [View Article][PubMed]
    [Google Scholar]
  108. Ou J., DeLany J. P., Zhang M., Sharma S., O’Keefe S. J. D. 2012; Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations. Nutr Cancer 64:34–40 [View Article][PubMed]
    [Google Scholar]
  109. Pavlović N., Stankov K., Mikov M. 2012; Probiotics–interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol 169:1880–1895 [View Article]
    [Google Scholar]
  110. Pearson J. R., Gill C. I., Rowland I. R. 2009; Diet, fecal water, and colon cancer–development of a biomarker. Nutr Rev 67:509–526 [View Article][PubMed]
    [Google Scholar]
  111. Prakash S., Rodes L., Coussa-Charley M., Tomaro-Duchesneau C. 2011; Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 5:71–86[PubMed]
    [Google Scholar]
  112. Prescott S. C. 1912; The bacteriology of fermentation and putrefaction in relation to the conservation of foods. Am J Public Health (N Y) 2:834–839 [View Article][PubMed]
    [Google Scholar]
  113. Prince T., McBain A. J., O’Neill C. A. 2012; Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion. Appl Environ Microbiol 78:5119–5126 [View Article][PubMed]
    [Google Scholar]
  114. Pufulete M. 2008; Intake of dairy products and risk of colorectal neoplasia. Nutr Res Rev 21:56–67 [View Article][PubMed]
    [Google Scholar]
  115. Qin J., Li R., Raes J., Arumugam M., Burgdorf K. S., Manichanh C., Nielsen T., Pons N., Levenez F. other authors 2010; A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59–65 [View Article][PubMed]
    [Google Scholar]
  116. Rafter J. 2001; Probiotics as dietary supplements can have a cancer-preventive effect. But the epidemiological studies are contradictory. Lakartidningen 98:5732–5734 (in Swedish) [PubMed]
    [Google Scholar]
  117. Rafter J. 2003; [Probiotics and colon cancer]. Best Pract Res Clin Gastroenterol 17:849–859 [View Article][PubMed]
    [Google Scholar]
  118. Rafter J., Bennett M., Caderni G., Clune Y., Hughes R., Karlsson P. C., Klinder A., O’Riordan M., O’Sullivan G. C. other authors 2007; Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 85:488–496[PubMed]
    [Google Scholar]
  119. Ramasamy S., Singh S., Taniere P., Langman M. J., Eggo M. C. 2006; Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation. Am J Physiol Gastrointest Liver Physiol 291:G288–G296 [View Article][PubMed]
    [Google Scholar]
  120. Ranadheera C. S., Evans C., Adams M., Baines S. 2012; In vitro analysis of gastrointestinal tolerance and intestinal cell adhesion of probiotics in goat's milk ice cream and yogurt. Food Res Int 49:619–625 [View Article]
    [Google Scholar]
  121. Rescigno M. 2008; The pathogenic role of intestinal flora in IBD and colon cancer. Curr Drug Targets 9:395–403 [View Article][PubMed]
    [Google Scholar]
  122. Roessler A., Forssten S., Glei M., Ouwehand A., Jahreis G. 2011; The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: A randomized, placebo-controlled study. Clin Nutr 31:22–29[PubMed] [CrossRef]
    [Google Scholar]
  123. Roldán M. D., Pérez-Reinado E., Castillo F., Moreno-Vivián C. 2008; Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev 32:474–500 [View Article][PubMed]
    [Google Scholar]
  124. Roller M., Clune Y., Collins K., Rechkemmer G., Watzl B. 2007; Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients. Br J Nutr 97:676–684 [View Article][PubMed]
    [Google Scholar]
  125. Rowland I. R. 2009; The role of the gastrointestinal microbiota in colorectal cancer. Curr Pharm Des 15:1524–1527 [View Article][PubMed]
    [Google Scholar]
  126. Scanlan P. D., Shanahan F., Clune Y., Collins J. K., O’Sullivan G. C., O’Riordan M., Holmes E., Wang Y., Marchesi J. R. 2008; Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 10:789–798 [View Article][PubMed]
    [Google Scholar]
  127. Scharlau D., Borowicki A., Habermann N., Hofmann T., Klenow S., Miene C., Munjal U., Stein K., Glei M. 2009; Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res 682:39–53 [View Article][PubMed]
    [Google Scholar]
  128. Schiffman M. H., Andrews A. W., Van Tassell R. L., Smith L., Daniel J., Robinson A., Hoover R. N., Rosenthal J., Weil R. other authors 1989; Case-control study of colorectal cancer and fecal mutagenicity. Cancer Res 49:3420–3424[PubMed]
    [Google Scholar]
  129. Schiffman M. H., Van Tassell R., Andrews A. W. 1990; Epidemiologic studies of fecal mutagenicity, cooked meat ingestion, and risk of colorectal cancer. Prog Clin Biol Res 340E:205–214[PubMed]
    [Google Scholar]
  130. Schreiber R., Nishimura T., Vivier E., Ugolini S., Karin M., Herber D., Cao W., Nefedova Y., Novitskiy S., Nagaraj S. 2010 Immune Surveillance and Tumor Immunity (SY2–5) SY2–5-1 Cancer Immunoediting: Basic Mechanisms and Therapeutic Implications SY2–5-2 Overcoming Immunosuppressive Tumor-escape Mechanisms by Th1 Cell Therapy-From Basic to Clinical Study-SY2–5-3 Regulation of Natural Killer Cell Function SY2–5-4 Innate Responses to Injury and Death as Promoters of Tumor Progression and Metastasis SY2–5-5 Lipid Accumulation and Dendritic Cell Dysfunction in Cancer SY2–5-6 Molecular Bases of the Immunogenicity of Cell Death in Cancer Oxford University Press;
    [Google Scholar]
  131. Sears C. L., Pardoll D. M. 2011; Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis 203:306–311 [View Article][PubMed]
    [Google Scholar]
  132. Seitz H. K., Becker P. 2007; Alcohol metabolism and cancer risk. Alcohol Res Health 30:38–41, 44–47[PubMed]
    [Google Scholar]
  133. Shen X. J., Rawls J. F., Randall T., Burcall L., Mpande C. N., Jenkins N., Jovov B., Abdo Z., Sandler R. S., Keku T. O. 2010; Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 1:138–147 [View Article][PubMed]
    [Google Scholar]
  134. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C. other authors 2012; Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241 [View Article][PubMed]
    [Google Scholar]
  135. Silva F. C., Valentin M. D., Ferreira F. O., Carraro D. M., Rossi B. M. 2009; Mismatch repair genes in Lynch syndrome: a review. Sao Paulo Med J 127:46–51 [View Article][PubMed]
    [Google Scholar]
  136. Sobhani I., Tap J., Roudot-Thoraval F., Roperch J. P., Letulle S., Langella P., Corthier G., Tran Van Nhieu J., Furet J. P. 2011; Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE 6:e16393 [View Article][PubMed]
    [Google Scholar]
  137. Steffensen I. L., Paulsen J. E., Alexander J. 1997; [Genetic and environmental factors in colorectal cancer. Mutations in the familial adenomatous polyposis gene]. Tidsskr Nor Laegeforen 117:2046–2051 (in Norwegian) [PubMed]
    [Google Scholar]
  138. Stetinova V., Smetanova L., Kvetina J., Svoboda Z., Zidek Z., Tlaskalova-Hogenova H. 2010; Caco-2 cell monolayer integrity and effect of probiotic Escherichia coli Nissle 1917 components. Neuroendocrinol Lett 31:Suppl 251–56[PubMed]
    [Google Scholar]
  139. Strus M., Janczyk A., Gonet-Surowka A., Brzychczy-Wloch M., Stochel G., Kochan P., Heczko P. B. 2009; Effect of hydrogen peroxide of bacterial origin on apoptosis and necrosis of gut mucosa epithelial cells as a possible pathomechanism of inflammatory bowel disease and cancer. J Physiol Pharmacol 60:Suppl 655–60[PubMed]
    [Google Scholar]
  140. Sultana K., Godward G., Reynolds N., Arumugaswamy R., Peiris P., Kailasapathy K. 2000; Encapsulation of probiotic bacteria with alginate-starch and evaluation of survival in simulated gastrointestinal conditions and in yoghurt. Int J Food Microbiol 62:47–55 [View Article][PubMed]
    [Google Scholar]
  141. Šušković J., Kos B., Beganović J., Leboš Pavunc A., Habjanič K., Matošić S. 2010; Antimicrobial activity–the most important property of probiotic and starter lactic acid bacteria. Food Technol Biotechnol 48:296–307
    [Google Scholar]
  142. Switzer C. H., Glynn S. A., Ridnour L. A., Cheng R. Y. S., Vitek M. P., Ambs S., Wink D. A. 2011; Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci 32:644–651 [View Article][PubMed]
    [Google Scholar]
  143. Takagi A., Ikemura H., Matsuzaki T., Sato M., Nomoto K., Morotomi M., Yokokura T. 2008; Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse. J Gastroenterol 43:661–669 [View Article][PubMed]
    [Google Scholar]
  144. Thirabunyanon M., Boonprasom P., Niamsup P. 2009; Probiotic potential of lactic acid bacteria isolated from fermented dairy milks on antiproliferation of colon cancer cells. Biotechnol Lett 31:571–576 [View Article][PubMed]
    [Google Scholar]
  145. Tlaskalová-Hogenová H., Stěpánková R., Kozáková H., Hudcovic T., Vannucci L., Tučková L., Rossmann P., Hrnčíř T., Kverka M. other authors 2011; The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8:110–120 [View Article][PubMed]
    [Google Scholar]
  146. Tomaro-Duchesneau C., Saha S., Malhotra M., Coussa-Charley M., Kahouli I., Jones M. L., Labbé A., Prakash S. 2012a; Probiotic ferulic acid esterase active Lactobacillus fermentum NCIMB 5221 APA microcapsules for oral delivery: preparation and in vitro characterization. Pharmaceuticals 5:236–248 [View Article]
    [Google Scholar]
  147. Tomaro-Duchesneau C., Saha S., Malhotra M., Kahouli I., Prakash S. 2012b; Microencapsulation for the therapeutic delivery of drugs, live mammalian and bacterial cells, and other biopharmaceutics: Current status and future directions. J Pharmaceutics2013
    [Google Scholar]
  148. Uccello M., Malaguarnera G., Basile F., D'agata V., Malaguarnera M., Bertino G., Vacante M., Drago F., Biondi A. 2012; Potential role of probiotics on colorectal cancer prevention. BMC Surg 12:S35 [CrossRef]
    [Google Scholar]
  149. Ullman T. A., Itzkowitz S. H. 2011; Intestinal inflammation and cancer. Gastroenterology 140:1807–1816, 1816.e1 [View Article][PubMed]
    [Google Scholar]
  150. Urbanska A. M., Bhathena J., Martoni C., Prakash S. 2009; Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc(Min/+) mice. Dig Dis Sci 54:264–273 [View Article][PubMed]
    [Google Scholar]
  151. Uronis J. M., Mühlbauer M., Herfarth H. H., Rubinas T. C., Jones G. S., Jobin C. 2009; Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS ONE 4:e6026 [View Article][PubMed]
    [Google Scholar]
  152. Wada M., Nagata S., Saito M., Shimizu T., Yamashiro Y., Matsuki T., Asahara T., Nomoto K. 2010; Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 18:751–759 [View Article][PubMed]
    [Google Scholar]
  153. Wang S., Zhang L., Gu W. 2012; Effects of lactobacillus strains on colon cancer cell proliferation and cell cycle blockage. Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference. IEEE; Macao:
    [Google Scholar]
  154. Watson J. 2013; Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3:120144 [View Article][PubMed]
    [Google Scholar]
  155. Watson A. J., Chu S., Sieck L., Gerasimenko O., Bullen T., Campbell F., McKenna M., Rose T., Montrose M. H. 2005; Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 129:902–912 [View Article][PubMed]
    [Google Scholar]
  156. Wollowski I., Rechkemmer G., Pool-Zobel B. L. 2001; Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 73:Suppl451S–455S[PubMed]
    [Google Scholar]
  157. Wong J. M., de Souza R., Kendall C. W., Emam A., Jenkins D. J. 2006; Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 40:235–243 [View Article][PubMed]
    [Google Scholar]
  158. Worthley D. L., Le Leu R. K., Whitehall V. L., Conlon M., Christophersen C., Belobrajdic D., Mallitt K.-A., Hu Y., Irahara N. other authors 2009; A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am J Clin Nutr 90:578–586 [View Article][PubMed]
    [Google Scholar]
  159. Xia Y., Yang Z., Chen H. Q., Qin H. L. 2010; [Effect of bowel preparation with probiotics on intestinal barrier after surgery for colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 13:528–531 (in Chinese) [PubMed]
    [Google Scholar]
  160. Yan F., Polk D. B. 2012; Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes 3:25–28 [View Article][PubMed]
    [Google Scholar]
  161. Zampa A., Silvi S., Fabiani R., Morozzi G., Orpianesi C., Cresci A. 2004; Effects of different digestible carbohydrates on bile acid metabolism and SCFA production by human gut micro-flora grown in an in vitro semi-continuous culture. Anaerobe 10:19–26 [View Article][PubMed]
    [Google Scholar]
  162. Zhang J. W., Du P., Chen D. W., Cui L., Ying C. M. 2010; [Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 13:40–43 (in Chinese) [PubMed]
    [Google Scholar]
  163. Zhang J. W., Du P., Gao J., Yang B. R., Fang W. J., Ying C. M. 2012; Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci 343:199–205 [View Article][PubMed]
    [Google Scholar]
  164. Zhu Y., Michelle Luo T., Jobin C., Young H. A. 2011; Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 309:119–127 [View Article][PubMed]
    [Google Scholar]
  165. Zhu D., Chen X., Wu J., Ju Y., Feng J., Lu G., Ouyang M., Ren B., Li Y. 2012; [Effect of perioperative intestinal probiotics on intestinal flora and immune function in patients with colorectal cancer]. Nan Fang Yi Ke Da Xue Xue Bao 32:1190–1193 (in Chinese) [PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.048975-0
Loading
/content/journal/jmm/10.1099/jmm.0.048975-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error